Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 1, 2008, Pages 75-83

  Nakade, Susumu ^a   Ohno, Tomoya ^a   Kitagawa, Junsaku ^a   Hashimoto, Yoshitaka ^a   Katayama, Masahiro ^a   Awata, Hiroshi ^a   Kodama, Yasuo ^b   Miyata, Yasuyuki ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

^b JOSAI INTERNATIONAL UNIVERSITY   (Japan)

Author keywords

Aprepitant; Chemotherapy induced nausea and vomiting; Dexamethasone; Population pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; ASPARTATE AMINOTRANSFERASE; DEXAMETHASONE; GRANISETRON; PLACEBO;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; POPULATION MODEL; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; GRANISETRON; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MORPHOLINES; NAUSEA; VOMITING;

EID: 53149119534     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0713-y     Document Type: Article

References (25)

1. AE Aranda FM Constenla H Cortes-Funes GE Diaz-Rubio VP Gascon V Guillem S Martin-Algarra 2005 Clinical practice guidelines on antiemetics in oncology Expert Rev Anticancer Ther 5 963
2. Beal SL, Sheiner LB (1989-2006) NONMEM Users Guides. Icon Development Solutions, Ellicott City, Maryland, USA
3. AJ Bergman T Marbury T Fosbinder S Swan L Hickey TE Bradstreet J Busillo KJ Petty KJ Aiyer M Constanzer SE Huskey A Majumdar 2005 Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant Clin Pharmacokinet 44 637
4. RA Blum A Majumdar J McCrea J Busillo LH Orlowski D Panebianco M Hesney KJ Petty MR Goldberg MG Murphy KM Gottesdiener CM Hustad C Lates WK Kraft S Van Buren SA Waldman HE Greenberg 2003 Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects Clin Ther 25 1407
5. D Campos JR Pereira RR Reinhardt C Carracedo S Poli C Vogel J Martinez-Cedillo A Erazo J Wittreich LO Eriksson AD Carides BJ Gertz 2001 Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone J Clin Oncol 19 1759
6. DW Cockcroft MH Gault 1976 Prediction of creatinine clearance from serum creatinin Nephron 16 31
7. ML Constanzer CM Chavez-Eng J Dru WF Kline BK Matuszewski 2004 Determination of a novel substance P inhibitor in human plasma by high-performance liquid chromatography with atmospheric pressure chemical ionization mass spectrometric detection using single and triple quadrupole detectors J Chromatogr B 807 243
8. R de Wit J Herrstedt B Rapoport AD Carides G Carides M Elmer C Schmidt JK Evans KJ Horgan 2003 Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy J Clin Oncol 21 4105
9. R de Wit J Herrstedt B Rapoport AD Carides J Guoguang-Ma M Elmer C Schmidt JK Evans KJ Horgan 2004 The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials Eur J Cancer 40 403
10. ® product information. Weat Point, PA: Merck & Co., INC., 2003
11. EI Ette 1997 Stability and performance of a population pharmacokinetics model J Clin Pharmacol 37 486
12. DM Gentile ES Tomlinson JL Maggs BK Park DJ Back 1996 Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation J Pharmacol Exp Ther 277 105
13. PJ Hesketh SM Grunberg RJ Gralla DG Warr F Roila R de Wit SP Chawla AD Carides J Ianus ME Elmer JK Evans K Beck S Reines KJ Horgan 2003 The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group J Clin Oncol 21 4112
14. SE Huskey BJ Dean GA Doss Z Wang CE Hop R Anari PE Finke AJ Robichaud M Zhang B Wang JR Strauss PK Cunningham WP Feeney RB Franklin TA Baillie SH Chiu 2003 The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs Drug Metab Dispos 32 246
15. SX Li E Pequignot D Panebianco P Lupinacci A Majumdar L Rosen T Ahmed JE Royalty TH Rushmore MG Murphy KJ Petty 2006 Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers J Clin Pharmacol 46 792
16. AK Majumdar JB McCrea DL Panebianco M Hesney J Dru M Constanzer MR Goldberg G Murphy KM Gottesdiener CR Lines KJ Petty RA Blum 2003 Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe Clin Pharmacol Ther 74 150
17. AK Majumdar L Howard MR Goldberg L Hickey M Constanzer PL Rothenberg TM Crumley D Panebianco TE Bradstreet AJ Bergman SA Waldman HE Greenberg K Butler A Knops I De Lepeleire N Michiels KJ Petty 2006 Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers J Clin Pharmacol 46 291
18. AK Majumdar KX Yan DV Selverian S Barlas M Constanzer J Dru JB McCrea T Ahmed GS Frick WK Kraft KJ Petty HE Greenberg 2007 Effect of aprepitant on the pharmacokinetics of intravenous midazolam J Clin Pharmacol 47 744
19. JB McCrea AK Majumdar MR Goldberg M Iwamoto C Gargano DL Panebianco M Hesney CR Lines KJ Petty PJ Deutsch MG Murphy KM Gottesdiener DR Goldwater RA Blum 2003 Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone Clin Pharmacol Ther 74 17
20. RM Navari RR Reinhardt RJ Gralla MG Kris PJ Hesketh A Khojasteh H Kindler TH Grote K Pendergrass SM Grunberg AD Carides BJ Gertz 1999 Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group N Engl J Med 340 190
21. TH Oo PJ Hesketh 2005 Drug insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting Nat Clin Pract Oncol 2 196
22. J Parke NH Holford BG Charles 1999 A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models Comput Methods Programs Biomed 59 19
23. AK Shah TL Hunt SC Gallagher MT Cullen Jr 2005 Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers Curr Med Res Opin 21 595
24. K Yoshihara Y Gao H Shiga DR Wada M Hisaoka 2005 Population pharmacokinetics of olmesartan follwing oral administration of its prodrug, olmesartan medoxomil Clin Pharmacokinet 44 1329
25. T Varis KT Kivistö JT Backman PJ Neuvonen 2000 The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect Clin Pharmacol Ther 68 487